believed that the extensive published data on biological variation, generated for the most part from adults of working age, should be and validly can be much more widely used in the interpretation of routine clinical biochemistry laboratory results. We suggest that it is only in acute situations (for example, plasma enzyme activity assays after myocardial infarction) or in the long-term in chronic conditions, when deterioration or amelioration is occurring, that currently available data on biological variation cannot be used.
believed that the extensive published data on biological variation, generated for the most part from adults of working age, should be and validly can be much more widely used in the interpretation of routine clinical biochemistry laboratory results. We suggest that it is only in acute situations (for example, plasma enzyme activity assays after myocardial infarction) or in the long-term in chronic conditions, when deterioration or amelioration is occurring, that currently available data on biological variation cannot be used.
It would be of much interest to test this hypothesis further, in particular to assess components of biological variation in patients with specific diseases over longer time periods. 
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animal vs human sources of enzymes used in quality control
The suitability of control materials for determination of total amylase (EC 3.2.1.1) activity has been studied (1). The authors used 11 common techniques (five different principles) and processed the results by statistical methods. However, the analytical techniques they used did not measure human pancreatic in the presence of human salivary amylase, or vice versa. The inhibitor method (2) can distinguish between human pancreatic and human salivary amylase, which has some clinical advantages. The method is based on different degrees of inhibition of the two isoenzymes by the Department of Medicine and Therapeutics, University College, Woodview, Belfield, Dublin 4, Ireland.
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protein inhibitor from wheat (3). In contrast to the two human amylases, porcine pancreatic amylase is relatively resistant to the inhibitor (3). Because the amylase in many quality-control sera is of porcine or other animal origin, or is human serum with unspecified additions, the use of some of these products with the inhibitor method might give erroneous results. We examined the use of various commercially available quality-control sera in the measurement of human pancreatic and salivary amylase by the inhibitor method and report our findings here.
Materials and Methods
Quality-control sera: We studied 26 control sera from 11 suppliers, as follows: Ortho I and II (Ortho Diagnostics, Raritan, NJ 08869); Phadebas reference serum (Pharmacia Diagnostics, Uppsala, Sweden); Target, normal and abnormal (SmithKline Instruments, Sunnyvale, CA 94086); Du Pont, normal and elevated (Du Pont UK Ltd., Stevenage, Table 1 .
Differential amylase assay:
We tested all control sera by the inhibitor method (2), using slight modifications. Inhibitor solution, 10 L, containing about 190 milliunits of inhibitor (see below) were pre-incubated with 100 L of serum in a pre-incubation volume of 0.5 mL, for 25 mm. Samples containing total amylase values outside the range 80-500 UIL were brought into this range by dilution or by using increased aliquots of serum. Pre-incubation volumes were maintained at 0.5 mL. The remainder of the procedure was as described elsewhere (2).
Inhibitor preparation:
The inhibitor was purified to a specific activity of 1094 units/mg of protein by slight modification of the original method (3) as described by O'Connor and McGeeney (4). The inhibitor unit was defined as the quantity of inhibitor required to reduce the activity of 2.0 U of human salivary amylase by 50%, i.e., 1 unit of inhibitor inhibits 1.0 U of salivary amylase under our experimental conditions ( 
Animal amylases:
Dog, chicken, guinea pig, and rat pancreatic amylase were prepared from fresh pancreatic tissue by gel filtration on Bio-Gel P300 (Bio-Rad Laboratories, Richmond, CA 94804) as described elsehwere (5).
Acetone extracts of pancreas from ox, horse, sheep, cat, and rabbit were purchased from Sigma Chemical Co., Lendon, U.K. Amylase was purified from these sources by dissolving 10 mg of extract in phosphate buffer and applying 2 mL of solution to a gel-ifitration column (Bio-Gel P300) as described (5). Purified porcine pancreatic amylase was purchased from Sigma, and used without further purification.
Results and Discussion
The inhibitor method for measuring human amylase isoenzymes (2) is based on different degrees of inhibition of salivary and pancreatic amylase by the inhibitor. The total amylase activity (T) of the sample is measured, as is the amylase activity remaining (Ar) when the inhibitor is added to the sample. Because the inhibitor inactivates 90% of salivary amylase, AnT = 0.1 for the salivary enzyme; AnT = 0.8 for pancreatic enzyme-i.e., it is 20% inactivated. AnT values in the range 0.1-0.8 are obtained for combinations of the two enzymes, giving a standard curve as shown in Figure 1 . AnT values for many of the control sera fell outside the standard curve (values not shown). The samples fell into two groups: those containing human enzymes and those containing enzymes from nonhuman sources. With one exception, samples based on human serum gave ArPF values that fell on the standard curve (those samples are indicated in Table 1 ), but 14 of 18 samples containing animal enzymes gave values exceeding 0.8 and lay outside the standard curve.
The results can be explained by different degrees of inhibition of many animal amylases as compared with human amylase ( Table 2 ). The amylase in most control sera appears from the manufacturers' literature to be pancreatic type and of bovine, equine, or porcine origin. As Table 2 shows, these three sources of pancreatic amylase are quite insensitive to the inhibitor as compared with human pancreatic amylase. Supplemented with dog, chicken, or rat actIvity pancreatic amylase, control material will react to the inhibiremaining tor more like human salivary aniylase than human pancre1oo atic amylase. 100
When porcine pancreatic amylase is mixed with human 1oo salivary amylase in various proportions and analyzed, the 97 standard curve obtained is quite different from that given by mixtures of human amylases (Figure 1 ). This explains why AnT values for many sera containing pancreatic amylase from animal sources will exceed 0.8 at high ratios of porcine 41 pancreatic amylase/human salivary amylase. Even at low 34
AnT values, quantification of pancreatic and salivary amy-25 lase would not be accurate. Figure 1 also shows that the 10 standard curve for known ratios of human salivary amylase and Precinorm E amylase is superimposable on the standard curve for human salivary amylase and porcine pancre- atic amylase. This indicates that the amylase in Precinorm E has the properties of porcine pancreatic amylase. We conclude, therefore, that quality-control sera should be based on human serum and that their enzyme activities should be supplemented by amylases of human origin. In contrast with the situation found for total amylase assay (1), control material based on bovine or other animal sera could not be accurately analyzed by the inhibitor method. There are many situations where a knowledge of the activities of human pancreatic and salivary amylase in serum is clinically important, and a simple, inexpensive method of measuring them is desirable (6). The inhibitor method has now been adapted to a commercially available kit (Phanmacia Diagnostics, Uppsala, Sweden).
